Clinical Trials Logo

Dialysis clinical trials

View clinical trials related to Dialysis.

Filter by:

NCT ID: NCT00858260 Completed - Dialysis Clinical Trials

Arnogene: A Phosphocalcic Study in Dialysis

ARNOGENE
Start date: November 2008
Phase: N/A
Study type: Observational

Searching for high morbi-mortality risk Klotho variants in dialysis patients

NCT ID: NCT00772382 Completed - Clinical trials for Chronic Kidney Disease

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Start date: December 2008
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.

NCT ID: NCT00767897 Completed - Clinical trials for Chronic Kidney Disease

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

Start date: November 2011
Phase:
Study type: Observational

The proposed study is a pilot study and a first step towards developing an optimized HPV vaccination strategy for girls who have CKD, or are on dialysis or have a kidney transplant.

NCT ID: NCT00767637 Completed - Hyperphosphatemia Clinical Trials

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

Start date: June 2005
Phase: Phase 2
Study type: Interventional

To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis

NCT ID: NCT00544492 Completed - Dialysis Clinical Trials

Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients

Start date: October 2007
Phase: Phase 4
Study type: Interventional

A. Pain and other disadvantages of AV fistula cannulation can be limited by using the so-called buttonhole technique. B. Till present in our center catheters with cylindrical points are used for cannulation of AV fistulas with the rope ladder technique. One can hypothesize that a catheter with a bevel point might have some advantages such as a larger entrance area and less traumatic cannulation. The latter may influence pain sensation of the patients. The above background information gives rise to the following investigational questions: A. Buttonhole vs rope ladder technique 1. Is pain sensation different when using buttonhole cannulation as compared to rope ladder cannulation technique? Hypothesis: AV fistula cannulation by buttonhole technique causes less pain than cannulation by rope ladder technique. 2. Is the level of anxiety different when using buttonhole cannulation as compared to rope ladder cannulation technique? Hypothesis: AV fistula cannulation by buttonhole technique causes less anxiety than cannulation by rope ladder technique. 3. Is bleeding time different when using buttonhole cannulation as compared to rope ladder cannulation technique? Hypothesis: Bleeding time is shorter when using buttonhole technique versus rope ladder technique. 4. Is the number and severity of complications related to AV fistula cannulation different between buttonhole and rope ladder technique? Hypothesis: When using the buttonhole technique for AV fistula cannulation the number and severity of complications is less than when using the rope ladder technique. B. Rope ladder technique using catheters with cylindrical vs. bevel point 5. Is pain sensation different when using rope ladder cannulation catheters with cylindrical as compared to bevel point? Hypothesis: AV fistula cannulation using bevel point catheters causes less pain than cannulation using cylindrical point catheters.

NCT ID: NCT00542815 Completed - Clinical trials for Chronic Kidney Disease

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Start date: November 2007
Phase: Phase 3
Study type: Interventional

This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks

NCT ID: NCT00542386 Completed - Clinical trials for Chronic Kidney Disease

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Start date: December 2007
Phase: Phase 3
Study type: Interventional

This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.

NCT ID: NCT00537979 Completed - Clinical trials for Secondary Hyperparathyroidism

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Start date: September 2007
Phase: Phase 4
Study type: Interventional

Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.

NCT ID: NCT00506441 Completed - Clinical trials for Chronic Kidney Disease

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Start date: September 2007
Phase: Phase 3
Study type: Interventional

This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, flexible dose titration, the third period is a placebo-controlled withdrawal comparing MCI-196 with placebo for 4 weeks.

NCT ID: NCT00440869 Completed - Hemodialysis Clinical Trials

Effects of N-acetylcysteine on Muscle Fatigue in Hemodialysis

NAC
Start date: March 2007
Phase: Phase 1
Study type: Interventional

The purposes of the study are to determine whether oxidative stress causes the muscle of dialysis patients to tire more quickly than muscle of people without kidney disease and to determine whether treatment with N-acetylcysteine, an antioxidant, can improve muscle endurance.